BACKGROUND: The risk of progression to active tuberculosis is greatest in the several years following initial infection. The extent to which latent tuberculosis infection reduces the risk of progressive disease following reexposure and reinfection is not known. Indirect estimates from population models have been highly variable. METHODS: We reviewed prospective cohort studies of persons exposed to individuals with infectious tuberculosis that were published prior to the widespread treatment of latent tuberculosis to estimate the incidence of tuberculosis among individuals with latent tuberculosis infection (LTBI group) and without latent tuberculosis (uninfected; UI group). We calculated the incidence rate ratio (IRR) of tuberculosis disease following infection between these 2 groups. We then adjusted incidence for expected reactivation, proportion of each group that was infected, and median time of observation following infection during the study. RESULTS: We identified 18 publications reporting tuberculosis incidence among 23 paired cohorts of individuals with and without latent infection (total N = 19 886). The weighted mean adjusted incidence rate of tuberculosis in the LTBI and UI groups attributable to reinfection was 13.5 per 1000 person-years (95% confidence interval [CI]: 5.0-26.2 per 1000 person-years) and that attributable to primary infection was 60.1 per 1000 person-years (95% CI: 38.6-87.4 per 1000 person-years). The adjusted IRR for tuberculosis in the LTBI group compared with the UI group was 0.21 (95% CI: .14-.30). CONCLUSIONS: Individuals with latent tuberculosis had 79% lower risk of progressive tuberculosis after reinfection than uninfected individuals. The risk reduction estimated in this study is greater than most previous estimates made through population models.
BACKGROUND: The risk of progression to active tuberculosis is greatest in the several years following initial infection. The extent to which latent tuberculosis infection reduces the risk of progressive disease following reexposure and reinfection is not known. Indirect estimates from population models have been highly variable. METHODS: We reviewed prospective cohort studies of persons exposed to individuals with infectious tuberculosis that were published prior to the widespread treatment of latent tuberculosis to estimate the incidence of tuberculosis among individuals with latent tuberculosis infection (LTBI group) and without latent tuberculosis (uninfected; UI group). We calculated the incidence rate ratio (IRR) of tuberculosis disease following infection between these 2 groups. We then adjusted incidence for expected reactivation, proportion of each group that was infected, and median time of observation following infection during the study. RESULTS: We identified 18 publications reporting tuberculosis incidence among 23 paired cohorts of individuals with and without latent infection (total N = 19 886). The weighted mean adjusted incidence rate of tuberculosis in the LTBI and UI groups attributable to reinfection was 13.5 per 1000 person-years (95% confidence interval [CI]: 5.0-26.2 per 1000 person-years) and that attributable to primary infection was 60.1 per 1000 person-years (95% CI: 38.6-87.4 per 1000 person-years). The adjusted IRR for tuberculosis in the LTBI group compared with the UI group was 0.21 (95% CI: .14-.30). CONCLUSIONS: Individuals with latent tuberculosis had 79% lower risk of progressive tuberculosis after reinfection than uninfected individuals. The risk reduction estimated in this study is greater than most previous estimates made through population models.
Authors: R M G J Houben; J R Glynn; K Mallard; L Sichali; S Malema; P E M Fine; N French; A C Crampin Journal: Int J Tuberc Lung Dis Date: 2010-07 Impact factor: 2.373
Authors: Yuri F van der Heijden; Fareed Abdullah; Bruno B Andrade; Jason R Andrews; Devasahayam J Christopher; Julio Croda; Heather Ewing; David W Haas; Mark Hatherill; C Robert Horsburgh; Vidya Mave; Helder I Nakaya; Valeria Rolla; Sudha Srinivasan; Retna Indah Sugiyono; Cesar Ugarte-Gil; Carol Hamilton Journal: Tuberculosis (Edinb) Date: 2018-10-01 Impact factor: 3.131
Authors: Lisa V Adams; Barry N Kreiswirth; Robert D Arbeit; Hanna Soini; Lillian Mtei; Mecky Matee; Muhammad Bakari; Timothy Lahey; Wendy Wieland-Alter; Elena Shashkina; Natalia Kurepina; Jeffrey R Driscoll; Kisali Pallangyo; C Robert Horsburgh; C Fordham von Reyn Journal: J Clin Microbiol Date: 2012-05-30 Impact factor: 5.948
Authors: Chelsea Carpenter; John Sidney; Ravi Kolla; Kaustuv Nayak; Helena Tomiyama; Claudia Tomiyama; Oscar A Padilla; Virginie Rozot; Syed F Ahamed; Carlos Ponte; Valeria Rolla; Paulo R Antas; Anmol Chandele; John Kenneth; Seetha Laxmi; Edward Makgotlho; Valentina Vanini; Giuseppe Ippolito; Alexandra S Kazanova; Alexander V Panteleev; Willem Hanekom; Harriet Mayanja-Kizza; David Lewinsohn; Mayuko Saito; M Juliana McElrath; W Henry Boom; Delia Goletti; Robert Gilman; Irina V Lyadova; Thomas J Scriba; Esper G Kallas; Kaja Murali-Krishna; Alessandro Sette; Cecilia S Lindestam Arlehamn Journal: Tuberculosis (Edinb) Date: 2015-08-01 Impact factor: 3.131
Authors: Amanda Y Sun; Madhukar Pai; Henrik Salje; Srinath Satyanarayana; Sarang Deo; David W Dowdy Journal: Am J Epidemiol Date: 2013-10-07 Impact factor: 4.897
Authors: Cesar Boggiano; Katrin Eichelberg; Lakshmi Ramachandra; Jaqueline Shea; Lalita Ramakrishnan; Samuel Behar; Joel D Ernst; Steven A Porcelli; Markus Maeurer; Hardy Kornfeld Journal: Vaccine Date: 2017-05-02 Impact factor: 3.641
Authors: Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren Journal: Clin Microbiol Rev Date: 2012-10 Impact factor: 26.132
Authors: Mark Hatherill; Hendrik Geldenhuys; Bernadette Pienaar; Sara Suliman; Phalkun Chheng; Sara M Debanne; Daniel F Hoft; W Henry Boom; Willem A Hanekom; John L Johnson Journal: Vaccine Date: 2014-05-09 Impact factor: 3.641